DefinitionThis section has been translated automatically.
Very heterogeneous group of autoantibodies in terms of specificity, isotype and affinity, directed against phospholipids (cardiolipin, phosphaditylcholine, phosphatidylethanolamine, phosphaditylserine, phospaditylinositol).
They can be detected by 3 assay methods:
- Anti-Cardiolipin-AK (ACA)
- Lupus anticoagulant test
In vitro, the autoantibodies lead to a prolongation of the PTT, but also of the Quick value (lupus anticoagulant!); in vivo, however, accelerated coagulation, a tendency to thrombosis, abortions and thrombopenia occur, especially in the case of high-titer detection; see below. Antiphospholipid antibody syndrome).
General informationThis section has been translated automatically.
The secondary occurrence of antiphospholipid antibodies (PLA) has been associated with various underlying diseases:
- SLE (PLA pos. in 25-50% of patients)
- Sjögren's syndrome (42%)
- Rheumatoid arthritis (33%)
- Moschcowitz syndrome (30%)
- psoriatic arthritis (28%)
- systemic scleroderma (25%)
- Mixed connective tissue disease (22%)
- Polymyalgia rheumatica (20%)
- M. Behçet (20%)
- livedo racemosa
- Sneddon syndrome
- Antiphospholipid antibody syndrome
- Hashimoto's thyroiditis.
Phospholipid antibodies can interact with the platelet membrane due to their binding to phospholipids and thus act as co-factors in different stages of the coagulation cascade. In vivo, this results in a stronger activation of the coagulation system with a tendency to thrombosis.
Clinically, migrating thrombophlebitis can also be clinically impressive. The reaction of the phospholipid antibodies with central nervous membrane components can lead to CNS symptoms, e.g. dizziness, partial disturbance of short and long-term memory, disturbance of fine motor skills up to cerebral infarctions with hemiplegia and possible cerebral seizures.
Note(s)This section has been translated automatically.
Remember! The term "lupus anticoagulant" is actually a misnomer. Its detection is most strongly associated with an increased risk of thrombosis.
LiteratureThis section has been translated automatically.
- Asherson RA et al (2003) Antiphospholipid antibodies and infections. Ann Rheum Dis 62: 388-393
- Campos LM et al (2003) Antiphospholipid antibodies and antiphospholipid syndromes in 57 children and adolescents with systemic lupus erythematosus. Lupus 12: 820-826
- Fernandez-Galar M et al (2003) Systemic lupus erythematosus-associated anetoderma and anti-phospholipid antibodies. Clin Exp Dermatol 28: 39-42
- Lisi S et al (2003) A case of erythema elevatum diutinum associated with antiphospholipid antibodies. J Am Acad Dermatol 49: 963-964
- Mascarenhas R et al (2003) Familial Sneddon's syndrome. Eur J Dermatol 13: 283-287
- Meurer M, Degitz K (1992) Antiphospholipid antibodies. dermatologist 43: 11-13
- Sipek-Dolnicar A et al (2002) Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol 20: 335-342
- by Landenberg P et al (2003) Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48: 1939-1947
- Wall A, Disciple H (1992) Sneddon syndrome with detection of anti-phospholipid antibodies. dermatologist 43: 380-382